The Use of Bisphosphonates in Patients With Breast Cancer

Catherine H. Van Poznak, MD


Cancer Control. 2002;9(6) 

In This Article

Oral Bisphosphonates for Breast Cancer Bone Metastases

In the United States, only the intravenous pamidronate and zoledronic acid are approved by the FDA for treatment of osseous metastases. However, oral bisphosphonates have been clinically studied in the treatment of breast cancer metastases.[39] Where available, the oral bisphosphonate, clodronate, is efficacious in the treatment of breast cancer osseous metastases lesions.[40] A recent report of a phase III clinical trial of oral ibandronate demonstrated efficacy in the treatment of skeletal complications of malignancy in patients with osseous metastases from breast cancer.[41] Diel et al[42] compared oral clodronate, intravenous clodronate, and intravenous pamidronate in patients with osteolytic breast cancer lesions and demonstrated that the best pain reduction was obtained with intravenous pamidronate, followed by intravenous clodronate and then oral clodronate. The optimal bisphosphonate drug, route of administration, and schedule is yet to be defined; however, the intravenous route appears to be necessary to obtain optimal effects on bone pain.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.